Section Review—Central & Peripheral Nervous Systems: Therapeutic Potential of Cholecystokinin-B Antagonists

References

• MUTT V, JORPES J: Structure of porcine cholecystokinin-pancreozymin. Eur. J. Biochem. (1968) 6:156–162.
   PubMedGoogle Scholar
• FREY P: Cholecystokinin octapeptide (CCK 26-33) non-sulfated octapeptide and tetrapeptide (CCK 30-33) in rat brain: Analysis by high pressure liquid chromatogra-phy (HPLC) and radioimmunoassay (RIA). Neurocbem. Int. (1983) 5:811–815.
   PubMed Web of Science ®Google Scholar
• EYSSELEIN VE, BOTTCHER W, KAUFFMAN GL, WALSH pi:Molecular heterogeneity of canine cholecystokinin in portal and peripheral plasma. Regul. Pept. (1984) 9:173–184.
   PubMed Web of Science ®Google Scholar
• EBERLE1N GA, EYSSELEIN VE, GOEBELL H: Cholecystok-ittin-58 is the major molecular form in man, dog and cat but not in pig, beef and rat intestine. Peptides (1988) 9:993–998.
   PubMed Web of Science ®Google Scholar
• JOFINSON AH, REHFELD JF: Identification of cholecystokinin/gastrin peptides in frog and turtle. Eur. J. Biochem. (1992) 207:419–428.
   PubMedGoogle Scholar
• HUTCHINSON JB, DOCKRAY GJ: Inhibition of the action of cholecystokinin octapeptide on the guinea pig ileum myenteric plexus by dibutyryl cylic guanosine mono-phosphate. Brain Res. (1980) 202:501–505.
   PubMed Web of Science ®Google Scholar
• CRAWLEY JE, CORWIN RL: Biological actions of cholecystokinin. Peptides (1994) 15:731-755.Excellent, comprehensive review of CCK literature.
   Google Scholar
• EELTO-HUIKKO M, PEARSON H, SCHALLING M, HOKFELT T: Immunohistochemical demonstration of cholecystokinin-like immunoreactivity in spermatozoa In epididymis. Acta Physiol. Scand. (1989) 137:465–466.
   PubMedGoogle Scholar
• HOKFELT T, GERRERA-MARSCHITZ M, SEROOHYK, ET AL.: Immunohistochemical studies on cholecystokinin (CCK)-iminunoreactive neurons in the rat using se-quence specific antisera and with special reference to the caudate nucleus and primary sensory neurons. J. Chem. Neuroanat. (1988) 1:11–52.
   PubMedGoogle Scholar
• TANG F, MAN WSY: The regional distribution of thy-rotropin releasing hormone, LEU-enkaphalin, MET-enkephalin, substance P, somatostatin and cholecystokinin in the rat brain and pituitary. Neuropep-tides (1991) 19:287–292.
   PubMed Web of Science ®Google Scholar
• L1NDEFORS N, LINDEN A, BRENE S, SEDVALL G, PERSSONH: CCK peptides and mRNA in the human brain. Prog. Neurobiol. (1993) 40:671–69.
   PubMedGoogle Scholar
• SKIRBOLL L, HOKFELT T, REHFELD J, CUELLO AC, DOCK-RAY G: Coexistence of substance P-and cholecystok-inin-like immunoreactivity in neurons of the mesencephalic periaqueductal central gray. Neurosci. Lett. (1982) 28:35–39.
   PubMed Web of Science ®Google Scholar
• GALL C, LAUTERBORN J, BURKS D, SEROOGY K: Co-local-ization of enkephalin and cholecystokinin in discrete areas of rat brain. Brain Res. (1987) 403:403–408.
   PubMed Web of Science ®Google Scholar
• MEZEY E, REISINE TD, SKIRBOLL L, BEINFELD M, KISS JZ:Cholecystokinin in the medial parvocellular subdivi-sion of the paraventricular nucleus. Coexistence with corticotropin-releasing hormone. Ann. NY Acad. Sci. (1995) 448:152–156.
   Google Scholar
• VANDERHAEGHEN JJ, LOTSTRA F, VANDESANDE F, DIERICIOC K: Coexistence of cholecystokinin and oxyto-cin-neurophysin in some magnocellular hypothalamo-hypophyseal neurons. Cell Tissue Res. (1981) 221:227–231.
   PubMed Web of Science ®Google Scholar
• HENDRY SHC, JONES EG, DEFELTPE J, SCHECHEL D, BRAN-DON C, EMSON PC: Neuropeptide containing neurons of the cerebral cortex are also GABAergic. Proc. Natl, Acad. Sci. (1984) 81:6526–6530.
   PubMed Web of Science ®Google Scholar
• KOSAKA T, KOSAKA K, TATEISHI K, HAMAOKA Y, YANAI-HARA N, WU JY, HAMA K: GABAergic neurons containing CCK-8-like and/or VIP-like immunoreactivities in the rat hippocampus and dentate gyrus. J. Comp. Neurol. (1985) 239:420–430.
   PubMed Web of Science ®Google Scholar
• MCDONALD AJ, PEARSON JC: Coexistence of (ABA andpeptide imnaunoreactivity in non-pyramidal neurons of the basolateral amygdala. Neurosci. Lett. (1989) 100:53–58.
   PubMed Web of Science ®Google Scholar
• HOKFELT T, REHFELD JF, SKIRBOLL L, IVEMARK B, GOLD- STEIN M, MARKEY K: Evidence for coexistence of dopamine and CCK in mesolimbic neurons. Nature (1980) 285:476-478. Pioneering study in CCK neurophysiology.
   Google Scholar
• MORINO P, HERRERA-MARSCHITZ M, CASTEL MN, UNG-
   Google Scholar
• ERSTEDT U, VARRO A, DOCKRAY G, HOKFELT T: Cholecystokinin in cortico-striatal neurons in the rat: Immunohistochemical studies at the light and electron microscopical leveL Eur.J. Neuroscience (1994) 6:681-692. Detailed investigation of an important pathway that uses CCK as a neurotransmitter.
   Google Scholar
• MORINA P, MASCAGNI, MC DONALD A, HOKFELT T: Cholecystokinin corticostriatal pathway in the rat: Evi-dence for bilateral origin from medial prefrontal corti-cal areas. Neuroscience (1994) 59:939-952. Detailed investigation of an important pathway that uses CCK as a neurotransmitter.
   Google Scholar
• INNIS RB, SNYDER S: Distinct cholecystokinin receptors in brain and pancreas. Proc. NatL Acad. Sci. (1980) 77:6917-6921. First description of CCK receptor subtypes.
   Google Scholar
• HILL DR, WOODRUFF GN: Differentiation of central cholecystokinin receptor binding sites using the non-peptide antagonists MK-329 and L-365,260. Brain Res. (1990) 526:276–283.
   PubMed Web of Science ®Google Scholar
• WANK SA, HARKINS R, JENSEN RT, SHAPIRA H, WEERTHAD, SLATTERY T: Purification, molecular cloning, and functional expression of the cholecystokinin receptor from rat pancreas. Proc. Natl, Acad. Sci. (1992) 89:3125–3129.
   PubMed Web of Science ®Google Scholar
• DERR1EN M, MCCORT-TRANCHEPA1N 1, DUCOS B, RO-QUES BP, DURIEUX C: Heterogeneity of CCK-B receptors Involved in animal models of anxiety. Pharm. Biochem. Behavior (1994) 49:133–141.
   PubMed Web of Science ®Google Scholar
• JAGERSCHMIDT A, POROCIVI T, O'DONOHUE M, ROQUESBP: Identification and characterization of various cholecystokinin B receptor mRNA forms in rat brain tissue and partial determination of the cholecystokinin B receptor gene structure. J. Neurocbem. (1994) 63:1199–1206.
   PubMed Web of Science ®Google Scholar
• VERSPOHL EJ, HAFNER B, XLAOQIANG H, AND KNII tELJJ: Evidence for cholecystokinin receptor subtype in endocrine pancreas. Peptides (1994) 15:1353–1360.
   PubMed Web of Science ®Google Scholar
• SILVERMAN MA, GREENBERG RE, BANK S: Cholecystok- inin receptor antagonists: A review. Am.J. Gastro. (1987) 82:703–708.
   PubMed Web of Science ®Google Scholar
• BEGLINGER C, DILL S, MEYER B, WERTH B: Treatment of biliary colic with loxiglumide. Lancet (1989) 1167.
   Google Scholar
• SINGH L, FIELD MJ, HUGHES J, MENZIES R, OLES RJ, VASS CA, WOODRUFF GN: The behavioral properties of CI-988, a selective cholecystokinin-B receptor antagonist. Br. J. Pharmacol. (1991) 104:239–245.
   PubMed Web of Science ®Google Scholar
• ERVIN FR, PALMOUR RM, BRADWEJM J: A new primate model for panic disorder. Amer. Psych iat. Assoc. (1991) 144:(NR216) 100.
   Google Scholar
• DEMONT1GNY C: Cholecystokhiln tetrapeptide inducespanic-like attacks in healthy volunteers. Arch. Gen. Psychiatry (1989) 46:511–517.
   PubMedGoogle Scholar
• ABELSON JI, NEESE RM: Cholecystokinin-4 and panic. Arch. Gen. Psychiatry (1990) 47:395.
   PubMed Web of Science ®Google Scholar
• BRADWEJN J, KOSZYCKI D, SHRIQUI C, METERISSIAN G: Cholecystokinin tetrapeptide induces panic attacks in patients with panic disorder. Can. J. Psychiatry (1990) 35:83-85. Detailed study of a potential aetiology for panic disorder.
   Google Scholar
• PAVLASEVIC S, BEDNAR I, QURESHI GA, SOEDERSTEN P: Brain cholecystokinin tetrapeptide levels are increased in a rat model of anxiety. NeuroReport (1993) 5:225–228.
   PubMed Web of Science ®Google Scholar
• BARRETT JE, LINDEN MC, HOLLOWAY HC, YU MJ, HOW-BERT JJ: Anxiolytic-like effects of the CCK-B antagonists LY262691, LY262684, and LY247348 on punished re-sponding of squirrel monkeys. Soc. Neurosci. Abstr. (1991) 17:1063.
   Google Scholar
• POWELL KR, BARRETT JE : Evaluation of the effects of PD134308 (CI-988), a CCK-B antagonist, on the punished responding of squirrel monkeys. Neuropeptides (1991) 19:75–78.
   PubMed Web of Science ®Google Scholar
• RATAUD J, DARCHE F, PIOT 0, STUTZMANN JM, BOHMEGA, BLANCHARD JC: Anxiolytic effect of CCK-antago-nists on plus-maze behavior in mice. Brain Res. (1991) 548:315–317.
   PubMed Web of Science ®Google Scholar
• HELTON DR, BERGER JE, CZACHURA JF, RASMUSSEN KM, KALMAN MJ: Central nervous system characterization of the new cholecystokinin-B antagonist LY288513. Pharm. Biochem. Beb. (1995). In press.
   Google Scholar
• SINGH L, FIELD MJ, VASS CA, HUGHES J, WOODRUFF GN: The antagonism of benzodiazepine withdrawal effects by the selective cholecystoldnin-B receptor antagonist CI-988. Br. J. Pharmacol. (1992)105:9–10.
   Google Scholar
• RASMUSSEN K, HELTON DR, BERGER JE, SCEARCE E: The CCK-B antagonist LY288513 blocks effects of diazepam withdrawal on auditory startle. NeuroReport (1993) 5:154–156.
   PubMed Web of Science ®Google Scholar
• HARRO J, LANG A, VASAR E: Long-term diazepam treat-ment produces changes in cholecystokinin receptor binding in rat brain. Eur. j Pharmacol. (1990) 180:77–83.
   PubMed Web of Science ®Google Scholar
• RAIFRAY M, SINGHVI S, WU P-Y, ANDREWS N, FILE SE: Benzodiazepiries increase preprocholecystokinin mes-senger RNA levels in rat brain. Eur. J. Pharmacol. Mol. Pharmacol. (1993) 245:193–196.
   PubMedGoogle Scholar
• BONNAFOUS C, MARTINEZ J, BUENO L: Involvement ofCCK-A and CCK-B receptor subtypes in duodenal and colonic motor alterations during precipitated dia•wpam withdrawaL Gastroenterology (1993) 104:A480.
   Google Scholar
• TALLMAN JF, GALLAGER DW: The GABA-ergic system: a locus of benzodiazepine action. (1985) 8:21–44.
   Google Scholar
• BRANCHEREAU P, CHAMPAGNAT J, ROQUES BP, DE-NAVIT-SAUBIE M: CCK modulates inhibitory synaptic transmission in the solitary complex through CCK-B sites. NeuroReport (1992) 3:909–912.
   PubMed Web of Science ®Google Scholar
• SHOWELL GA, BOURRAIN S, NEDUVELIL JG, FLETCHER SR, BADER R, WATT AP, FLETCHER AE, FREEDMAN SB, KEMP JA, MARSHALL GR, PATEL S, SMITH AJ, MATASSA VG: High-affinity and potent, water-soluble 5-amino-1,4-benzodiazepine CC.K-B/gastrin receptor antagonists containing a cationic solubilizing group. j Med. Chem. (1994) 37:719–721.
   Google Scholar
• LOSONCZY MF, DAVIDSON M, DAVIS JCL: The dopamine hypothesis of schizophrenia. In: Psychopharmacology: The third generation of progress. HY Meltzer (Ed.). Raven Press, New York (1987)715–726.
   Google Scholar
• BUNNEY BS, GRACE AA: Acute and chronic haloperidol treatment: comparison of effects on tulgral dopaminer-gic cell activity. Life Sci. (1987) 23:1715-1728. Introduction of a novel hypothesis (i.e., depolarisation inactivation) for the therapeutic action of antipsychotic drugs.
   Google Scholar
• CHIODO LA, BUNNEY BS, Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A10 midbrain ciopaminergic neurons. J. Neurosci. (1983) 3:1607-1619. Further refinment of depolarisation inactivation hypothesis of anti-psychotic drug action.
   Google Scholar
• WHITE JF, WANG RY: Differential effects of classical and atypical antipsychotic drugs on A9 and A10 dopamine neurons. Science (1983) 221:1054-1057. Further refinement of depolarisation inactivation hypothesis of an-tipsychotic drug action.
   Google Scholar
• RASMUSSEN K, STOCKTON ME, CZACHLTRA JF, HOWBERT JJ: Cholecystokinin (CCK) and schizophrenia: the selec-tive CCK-B antagonist LY262691 decreases midbrain dopamine unit activity. Eur J. Pharm. (1991) 209:135–138.
   PubMed Web of Science ®Google Scholar
• RASMUSSEN K, CZACHURA JF, STOCKTON ME, HOWBERT JJ: Electrophysiological effects of diphenylpyrazolidi-none CCK-B and CCK-A antagonists on midbrain dopamine neurons. J. Pharm. Exp. Ther. (1993) 264:480-488. Detailed preclinical investigation of the potential use of CCK-B antagonists as antipsychotics.
   Google Scholar
• RASMUSSEN K, VU MJ, CZACHURA JF: Quinazolinone cholecystokinin (CCK)-B antagonists decrease mid-brain dopamine unit activity. Synapse (1994) 17:278–282.
   PubMed Web of Science ®Google Scholar
• LID, SIMMONS RM, HOWBERT JJ, RASMUSSEN K, IYENGAR S: CCK-B receptors tonically modulate doparainergic neurons selectively: Neurochemical evaluation of LY288513. Soc. Neurosci. Abstr. (1993) 19:1547.
   Google Scholar
• GRACE AA, BUNNEY BS: Induction of depolarizationblock in midbrain dopamine neurons by repeated ad-ministration of haloperidol: Analysis using in vivo Intracellular recording. J. Pharm. Exp. Ther. (1986) 238:1092–1100.
   PubMed Web of Science ®Google Scholar
• RASMUSSEN K, HOWBERT JJ, STOCKTON ME: Inhibition of A9 and A10 dopamine cells by the cholecystoldnin-B antagonist LY262691: Mediation through feedback pathways from forebrain sites. Synapse (1993) 15:95–103.
   PubMed Web of Science ®Google Scholar
• ROTH RH, TAM SY, IDA Y, YANG jx, DEUTCH AY: Stress and the mesocorticolimbic systems. Ann. NY Acad. Sci. (1988) 537:138-147.82). 00
   Google Scholar
• SPRING B: Stress and schizophrenia: some definitional Issues. Schizophrenia Bull. (1981) 7:24–33.
   PubMed Web of Science ®Google Scholar
• DOHRENWEND BP, EGRI G: Recent stressful life events and episodes of schizophrenia. Schizophrenia Bull. (1981) 7:12–23.
   PubMed Web of Science ®Google Scholar
• ZHANG X, DAGERLIND A, ELIDE RP, CASTEL M-N, •BROBERGER C, WIESENFELD-HALLIN Z, HOKFELT T:Marked increase in cholecystokinin B receptor messen-ger RNA levels in rat dorsal root ganglia after peripheral axotomy. Neuroscience (1993) 57:227-233. Important study of a potential physiological role for CCK.
   Google Scholar
• JAKOB H, BECKMANN H: Circumscribed malformationand nerve cell alterations in the entorhinal cortex of schizophrenics. J. Neural Transm. [Gen. Sect.] (1994) 98:83–106.
   PubMed Web of Science ®Google Scholar
• BOGERTS B, LIEBERMAN JA, ASHTARI M, BILDER RM,DEGREEF G, LERNER G, JOHNS C, MASIAR S: Hippocant-pus-amygdala volumes and psychopathology in chronic schizophrenia. Biol. Psych. (1993) 33:236–246.
   PubMed Web of Science ®Google Scholar
• PALACIOS JM, SAVASTA M, MENGOD G: Does cholecystokinin colorAlise with dopamine in the hu-man substantia nigra? Brain Res. (1989) 488:369–375.
   Google Scholar
• SCHALLING M, FRIBERG K, SEOOGY K, RIEDERER P, BIRDE, SCHIFFMANN SN, MAILLEUX P, VANDERHAEGHEN JJ, KUGA S, GOLDSTEIN M, KITAHAMA K, LUPPI PH, JOUVET M, HOKFELT T: Analysis of expression of cholecystok-initt in dopamine cells in the ventral mesencephakm of several species and in humans with schizophrenia. Proc. Natl, Acad. Sci. (1990) 87:8427–8431.
   PubMedGoogle Scholar
• FARIS PL, KOMISARUK BR, WATKINS LR, AMYER DJ: Evi-dence of the neuropeptide cholecystokinin as an an-tagonist of opiate analgesia. Science (1983) 219:310–312.
   PubMed Web of Science ®Google Scholar
• GAUDREAU P, LAVIGNE GJ, QUIRION R: Cholecystokinin antagonists proglumide, lorglumide and benzotript, but not L-364,718, interact with brain opioid binding sites. Neuropeptides (1990) 16:51–55.
   PubMed Web of Science ®Google Scholar
• WISENFELD-HALLIN X, XU X-J, HUGHES J, HORWELL DC, HOKFELT T: PD134308, a selective antagonist of cholecystokinin type B receptor, enhances the analge-sic effect of morphine and synergistically interacts with intrathecal galanin to depress spinal nociceptive re-flexes. Proc. Natl. Acad. Sci. (1990) 87:7105–7109.
   PubMed Web of Science ®Google Scholar
• O'NEIL MF, DOLJRISH CT, TYE SJ, IVERSON SD: Blockadeof CCK-B receptors by L-365,260 induces analgesia in the squirrel monkey. Brain Res. (1990) 534:287–290.
   PubMed Web of Science ®Google Scholar
• DOURISH CT, O'NEIL MF, COUGHLAN J, KITCHENER SJ,HAWLEY D, IVERSEN SD: The selective CCK-B receptor antagonist L-365,260 enhances morphine analgesia and prevents morphine tolerance in the rat. Eur. J. Marina-col (1990) 176:35–44.
   Web of Science ®Google Scholar
• KELLY JP, LEONARD BE: An examination of CI 988 in 3animal models of depression. J. Psychopharm. (1992) 6:A14.
   Google Scholar
• DERRIEN M, DLTRIEUX C, AND ROQUES BP: Antidepres-sant-like effects of CCK-B antagonists in mice: antago-nism by naltrindole. Br. J. Pharmacol. (1994) 111:956–960.
   PubMed Web of Science ®Google Scholar
• HERNANDO F, FUENTES JA, ROQUES BP, AND RUIZ-GAYO M: The CCK-B receptor antagonist, L-365,260, elicits antidepressant-type effects in the forced-swim test in mice. (1994) 261:257-263.
   Google Scholar
• KATSUURA G, ITOH S: Passive avoidance deficit follow-ing intracerebroventricular administration of cholecystokinin tetrapeptide amide in rats. Peptides (1986) 7:809–814.
   PubMed Web of Science ®Google Scholar
• LEMAIRE M, PIOT 0, ROQUES BP, BOHMNE GA, BLANCHARD JC: Evidence for an endogenous cholecystokininergic balance in social memory. NeuroReport (1992) 3:929–932.
   PubMed Web of Science ®Google Scholar
• LEMAIRE M, BOEHME GA, PIOT 0, ROQUES BP, BLANCHARD JC: CCK-A and CCK-B selective receptor agonists and antagonists modulate olfactory recogni-tion in male rats. Psychopharmacol. (1994) 115:435–440.
   Web of Science ®Google Scholar
• BOCK MG, DIPARDO RM, EVANS BE, RIME RE, WHII1ER WL, GARSKY VM, GILBERT RE, LEIGHTON JL, CARSON KL, MELLIN EC, VEBER DF, CHANG RSL, LOTTI VJ, FREEDMAN SB, SMITH AJ, PATEL S, ANDERSON PS, FREIDINGER RM: Development of 1,4-benzodiazepine cholecystokinin type B antagonists. J. Med. Chem. (1993) 36:4276–4292.
   PubMed Web of Science ®Google Scholar
• GRASING K, UN J, FRAME V, MURPHY MG, COLAMESTA R, SWIGAR M, MORIKE K, MARCUS F, GIARDINA EG, BJORNS-SON T: Human pharmacokinetics/tolerability of L-365,260: A cholecystokinin-B agonist Clin. Pharmacol. Ther. (1993) 53:178.
   Web of Science ®Google Scholar
• MURPHY MG, SYTNIK B, KOVACS TOG, MERTZ H, EWANIK D, SHINGO S, LIN JH, GERTZ BJ, WALSH JH: The gastrin-receptor antagonist L-365,260 inhibits stimulated acid secretion in humans. Clin. Pharmacol. Ther. (1993) 54:533–539.
   PubMed Web of Science ®Google Scholar
• LINES C, TRAUB M, AMBROSE J: CCK and anxiety in normal volunteers. Neuropsychopharmacol. (1993) 9:181S–182S.
   Google Scholar
• BRAD WEJN J, KOSZYCKI D, COLTETOUX DE TERTRE A, VAN MEGEN H, DEN BOER J, WESTENBERG H, ANNABLE L: The panicogenic effects of cholecystokinin receptor antagonist, in patients with panic disorder. Arch. Gen. Psych. (1994) 51:486–493.
   PubMed Web of Science ®Google Scholar
• SRAMEK JJ, KRAMER MS, REINES SA, CUTLER NR: Pilot study of a CCK-B antagonist hi patients with panic disorder: preliminary findings. Anxiety (1995). In press. Among the first Phase II reports (along with 1851 and [871) of a CCK-B antagonist.
   Google Scholar
• UN JH, CHEN IW, LIEVENS H: The effect of dosage forms on oral absorption of L-365,260, a potent CCK-B recep-tor antagonist, in dogs. Pharm. Res. (1991) 8:S272.
   Google Scholar
• BOCK MG, DIPARDO RM, MELLIN EC, NEWTON RC, VEBER DF, FREEDMAN SB, SMITH AJ, PATEL S, KEMP JA, MAR-SHALL GR, FLETHER AE, CHAPMAN RE, ANDERSON PS, FREIDINGER RM: Second-generation benzodiazepine CCK-B antagonists. Development of subnanomolar analogs with selectivity and water solubility. J. Med. Chem. (1994) 37:722–724.
   Google Scholar
• PATEL S, SMITH AJ, CHAPMAN RE, FLETCHER AE, KEMP JA,MARSHALL GR, HARGREAVES RJ, RYECROFT W, IVERSEN LL, IVERSEN SD, BAKER R, SHOWELL GA, BOURRAIN S, NEDUVELLL JG, MATASSA VG, FREEDMAN SB: Biological properties of the benzodiazepine amidine derivative L-740,093, a cholecystokinin-B/gastrin receptor antago-nist with high affinity in vitro and high potency in vivo. Mol. Pharmacol. (1994) 46:943–948.
   PubMed Web of Science ®Google Scholar
• BRADWEJN J, KOSZYCKI D, PARADIS M, REECE P, HINTON •J, SEDMAN A: The effect of CI-988 on cholecystokinintetrapeptide-induced panic symptoms in healthy vol-unteers. Biol. Psychiatry (1995). In press.
   Google Scholar
• Among the first Phase II reports (along with [81] and [871) of a CCK-B antagonist.
   Google Scholar
• PATEL S, CHAPMAN KL, HEALD A, SMITH AJ, FREEDMANSB: Measurement of CNS activity of systemically admin-istered CCK-B antagonists by ex vivo binding. Eur. J. Pharm. (1994) 253:237–244.
   PubMed Web of Science ®Google Scholar
• ABELSON JL, CURTIS GC, NESSE R, FANTONE R, PYKE RE, •BAMMERT-ADAMS J: The effects of central cholecystok-Min receptor blockade on hypothalamic-pituitary-ad-renal and symptomatic responses to overnight withdrawal from alprazolam. Biol. Psychiatry (1995) 37:56-59. Among the first Phase II reports (along with [81] and [85]) of a CCK-B antagonist.
   Google Scholar
• HOCKER M, HUGHES J, FOLSCH UR, SCHMIDT WE: PD135158, a CCK-B/gastrin receptor antagonist, stimulates rat pancreatic enzyme secretion as a CCK-A receptor agonist Eur. J. Pharrn. (1993) 242:105–108.
   Web of Science ®Google Scholar
• SCHMASSMANN A, GARNER A, FLOGERZI B, HASAN MY,SANNER M, VARGA L, HALTER F: Cholecystokinin type B receptor antagonist PD-136,450 is a partial secretory agonist in the stomach and a full agonist in the pancreas of the rat Gut (1994) 35:270–274.
   Google Scholar
• TRIVEDI BK, PADIA JK, PRITCHARD MC, EDEN JM, KNEEN C, HILL DR, WEBDALE L, SUMAN-CHUHAN N, BODEN P, ROSE S, WRIGHT SD: Cholecystokinin-B receptor an-tagonists: design and development of PD-145942, a bioavailable CCK-B antagonist Am, Chem. Soc. (1994) 194:2.
   Google Scholar
• LOWE JA, HAGEMAN DL, DROZDA SE, MCLEAN S, BRYCEDK, CRAWFORD RT, ZORN S, MORRONE J, BORDNER J: 5-Phenyl-3-ureidobenzazepin-2-ones as cholecystok-inin-B receptor antagonists. J. Med. Chem. (1994) 37:3789–3811.
   PubMed Web of Science ®Google Scholar
• HOWBERT JJ, LOBB KL, BROWN FR, REEL JK, NEEL DA, MASON NR, MENDELSOHN LG: A novel series of non-pep-tide CCK and gastrin antagonists: medicinal chemistry and electrophysiological demonstration of antago-nism. In: Multiple cholecystokinin receptors - progress to-wards CNS therapeutic targets. Dourish CT, Cooper SJ (Eds.). Oxford University Press, London (1992):28–37.
   Google Scholar
• HENDRIE CA, DOURISH CT: Effects of cholecystokinin tetrapeptide (CCK-4) and the CCK-B antagonist LY-288513 in a putative model of panic in the mouse. Br. J. Pharmacol. (1993) 108:26P.
   Web of Science ®Google Scholar
• HOWBERT JJ, LOBB KL, BRITTON TC, MASON NR, BRUNS RF: Diphenylpyrazolidinone and benzodiazepine cholecystokinin antagonists: A case of convergent evo-lution in medicinal chemistry. Bioorganic & Medicinal Chemistry Letters (1993) 3:875–880.
   Web of Science ®Google Scholar
• YU MJ, THRASHER KJ, MCCOWAN JR, MASON NR, MEN-DELSOHN LG: Quinazolinone cholecystokinin-B recep-tor ligands. J. Med. Chem. (1991) 34:1505–1508.
   PubMed Web of Science ®Google Scholar
• SAITA Y, YAZAWA H, HONMA Y, NISHIDA A, MIYATA K,HONDA K: Characterization of YM022: its CCK-B/gastrin receptor binding profile and antagonism to CCK-8-in-duced Ca2+ mobilization. Molecular Pharmacol. (1994) 269:249–254.
   Web of Science ®Google Scholar
• NISHIDA A, MIYATA K, SUTSUMI R, HIDENOBY Y, AKUZAWA S, KOBAYASHI A, KAMATO T, ITO H, YAMANO M, KATUYAMA Y, SATOH M, OHTA M, HONDA K: Phar-macological profile of (R)-142,3-dihydro-1-(2'-methyl-phenacy1)-2-oxo-5-pheny1-1H-1,4-benzodiazepin-3-yl] -3-(3-methylphenyDurea (YM022), a new potent and selective gastrin/cholecystokinin-B receptor antago-nist in vitro and in vivo. J. Pharmacol. Exp. Therapeut. (1994) 269:725–731.
   PubMed Web of Science ®Google Scholar
• OHTSUKA T, KUDOH T, SHIMMA N, KOTAKI H, NAKAYAMA N, ITEZONO Y, FUJISAKI N, WATANABE J, YOKOSE K, SETO H: Tetronothiodin, a novel cholecystokinin type-B receptor antagonist produced by Streptomyces sp. J. Anti biot. (1992) 45:140–143.
   PubMed Web of Science ®Google Scholar
• BERTRAND P, BOHME GA, DURIEUX C, GUYON C, CAPET M, JEANTAUD B, BOUDEAU P, DUCOS B, PENDLEY CE, MARTIN GE, FLOCH A, DOBLE A: Pharmacological prop-erties of ureido-acetarnides, new potent and selective non-peptide CCK-B/gastrin receptor antagonists. Euro-pean J. Pharmacol. (1994) 262:233–245.
   PubMed Web of Science ®Google Scholar
• BOHME GA, BERTRAND P, PENDLEY C, DOBLE A, GUYON C, MARTIN G, STUTZMANN JM, DUBROEUCQ MC, BLANCHARD JC: RP 69758, a novel cholecystokinin B-type and gastrin antagonist NS Arch. Pharmacol. (1992) 345:R116.
   Google Scholar
• MAKOVEC F, PERIS W, REVEL L, GIOVANETTI R, MENNUNI L, ROVATI LC: Structure-antigastrin activity relation-ships of new (R)-4-benzamido-5-oxopentanoic acid de-rivatives. J. Med. Chem. (1992) 35:28–38.
   PubMed Web of Science ®Google Scholar
• REVEL L, FERRARI F, MAKOVEC F, ROVATI L, IMPICCIA-TORE M: Characterization of antigastrin activity in vivo of CR 2194, a new R-4-benzamido-5-oxo-pentanoic add derivative. European J. Pharmacol. (1992) 216:217–224.
   PubMed Web of Science ®Google Scholar
• BELTINGER J, HILDEBRAND P, HOWALD A, AMATO MD, BEGLINGER C: Effect of CR-2194, a CCK-B antagonist, on gastrin-stinaulated acid secretion in man. Gastroenterol-ogy (1994) 106:A50.
   Web of Science ®Google Scholar
• ROVATI IC, D'AMATO M, PERIS W, REVEL L, MAKOVEC F: Selectivity and potency of new basic CCK-B antagonists. In: Cholecystokinin. Reeve JR, Eysselein V, Go VLW, Solo-mon T (Eds.). Annals of the New York Academy of Sciences (1993):395–397.
   Google Scholar
• BLOMMAERT AGS, WENG J-H, DORVILLE A, MCCORT I, DUCOS B, DURIEUX C, ROQUES BP: Cholecystokinin peptidomimetics as selective CCK-B antagonists: De-sign, synthesis and in vitro and in vivo biochemical properties. J. Med. Chem. (1993) 36:2868–2877.
   PubMed Web of Science ®Google Scholar
• VALVERDE 0, MALDONADO R, ZALUSKI-FOURNIE MC, ROQUES BP: Cholecystokinin B antagonists strongly potentiate antinociception mediated by exogenous enkephalins. J. Pharmacol. Exp. Ther. (1994) 270:77–88.
   PubMed Web of Science ®Google Scholar
• KALINDJIAN SB, BODKIN MJ, BUCK IM, DUNSTONE DJ, LOW CMR, MCDONALD IM, PETHER MJ, STEEL KIM: Anew class of non-peptidic cholecystokinin-B/gastrin recep-tor antagonists based on dibenzobicyclo [2,2,21 octane. J. Med. Chem. (1994) 37:367/–3673.
   Google Scholar